Eli Lilly and Company (BKK:LLY80)

Market Cap	30.39T
Revenue (ttm)	1.93T
Net Income (ttm)	597.91B
Shares Out	n/a
EPS (ttm)	663.84
PE Ratio	50.83
Forward PE	34.44
Dividend	0.01 (0.34%)
Ex-Dividend Date	Nov 14, 2025

Volume	6,329,480
Average Volume	10,274,107
Open	1.690
Previous Close	1.680
Day's Range	1.690 - 1.740
52-Week Range	1.010 - 1.830
Beta	n/a
RSI	56.26
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: LLY80

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD